镇静——滥用障碍对治疗效果的影响(SEDATE):一项回顾性队列研究
该回顾性队列研究纳入2015至2020年五家急诊科的2725例成人程序镇静病例,按酒精使用障碍(AUD,59例)、阿片使用障碍(OUD,40例)及无物质使用障碍(non-SUD)分组。主要终点丙泊酚时间平均剂量在三组间无显著差异(non-SUD 0.033、AUD 0.042、OUD 0.058 mg/kg*min)。镇静持续时间及需多药镇静的比值比亦无差异。结论提示无证据支持对AUD或OUD急诊患者预防性调整镇静药物策略。
要点
- 五家急诊科2725例程序镇静回顾性分析中,AUD仅59例、OUD仅40例,样本量小且为回顾性设计。
- 丙泊酚时间平均剂量:non-SUD 0.033(IQR 0.04)、AUD 0.042(IQR 0.05)、OUD 0.058(IQR 0.04)mg/kg*min,组间无显著差异。
- AUD或OUD患者接受多药镇静的比值比无显著增加,镇静持续时间组间无差异。
- 原文结论:无证据支持对AUD或OUD急诊患者预防性调整镇静药物策略。
- 原文指出AUD/OUD患者镇静可能存在显著病例偏倚(case bias),解读结果需谨慎。
适用人群与场景
- 2015至2020年五家急诊科接受程序镇静的成人患者。
- 按预设三组分类:酒精使用障碍(AUD,59例)、阿片使用障碍(OUD,40例)、无物质使用障碍(non-SUD)。
- 原文未提及具体纳入/排除标准及急诊病情阶段。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体药物剂量方案、给药途径或目标值;仅报告丙泊酚时间平均剂量(mg/kg*min)作为研究观察指标,非推荐剂量。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性病历审查队列研究,五家急诊科,2015至2020年,共2725例程序镇静。
- 人群:成人急诊程序镇静患者,AUD 59例、OUD 40例、non-SUD其余。
- 主要终点:丙泊酚时间平均剂量(mg/kg*min),non-SUD 0.033(IQR 0.04)、AUD 0.042(IQR 0.05)、OUD 0.058(IQR 0.04),组间无显著差异。
- 次要终点:其他药物剂量、镇静持续时间、换用其他药物,组间均无显著差异;AUD或OUD与需多药镇静的比值比无显著增加。
证据类型、等级与局限
- 证据类型:回顾性队列研究(病历审查),非随机对照试验。
- 局限:回顾性设计、AUD(59例)与OUD(40例)样本量小、原文指出可能存在显著病例偏倚(case bias);原文未提及单中心或多中心偏倚控制细节。
对床旁实践的改变
- 原文结论提示:无证据支持对急诊AUD或OUD患者预防性调整程序镇静药物策略。
- 适用人群:急诊接受程序镇静的成人AUD或OUD患者;原文未提及不适用人群。
- 常见陷阱:原文指出AUD/OUD患者镇静可能存在显著病例偏倚,解读剂量差异时需谨慎;样本量小(AUD 59例、OUD 40例)限制结论外推。
指南或共识出处
- 原文未提及指南或共识出处;研究发表于Am J Emerg Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The impact of alcohol or opioid use disorders on medication dosing for procedural sedation in the emergency department (ED) is unclear, as most of the literature is from gastrointestinal endoscopy. Exploring how these patient factors affect sedative and analgesic medications may inform more nuanced sedation strategies in the emergency department.
METHODS: This was a retrospective chart-review cohort study across five EDs from 2015 to 2020. Included were adult patients who underwent procedural sedation in the ED, categorized into three a priori groups: alcohol use disorder (AUD), opioid use disorder (OUD), and individuals with neither (non-SUD). Wilcoxon test was used to compare the time-averaged dose of agents between groups. Logistic regression was used to model multi-agent sedations. The propofol time-averaged dose was the primary outcome. Secondary outcomes included other agents, sedation duration, and switching to other agents.
RESULTS: 2725 sedations were included in the analysis. 59 patients had a history of AUD, and 40 had a history of OUD. Time-averaged doses of medications did not differ significantly between AUD and non-SUD patients. Likewise, patients with OUD did not receive different doses of medications compared to non-SUD. The propofol doses for non-SUD, AUD, and OUD were 0.033 IQR 0.04; 0.042 IQR 0.05; and 0.058 IQR 0.04 mg/kg*min, respectively. Sedation duration was not different across groups. Having AUD or OUD is not associated with increased odds of requiring multiple sedative agents.
CONCLUSION: Although sedation in patients with AUD or OUD may be associated with significant case bias, these patient factors did not significantly alter outcomes compared to the general population. This study suggests there is no evidence to proactively adjust medication strategy in ED patients with AUD or OUD.
参考来源
- Albala L, Loesche MA, Hayes BD, et al. Sedation - Effects of disorders of abuse on therapeutic efficacy (SEDATE): A retrospective cohort study. Am J Emerg Med. 2021. PMID: 34182272. doi:10.1016/j.ajem.2021.06.023
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。